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the interactions between CVD and AD has led to the identifi-
cation of several novel therapeutic approaches that have the 
potential to ameliorate ischaemic damage and slow the pro-
gression of neurodegenerative disease.
Keywords Cerebrovascular disease · Alzheimer’s 
disease · Ageing · Hypoperfusion · Myelin proteins · 
Endothelin-1
Introduction
The relationship between age-associated cerebrovascu-
lar disease (CVD) and Alzheimer’s disease (AD) is com-
plex. They share multiple risk factors and overlap more 
often than not, to an extent that increases with age. Whilst 
there is clearly an additive component to the clinical and 
pathological effects of CVD and AD, increasing evidence 
suggests that the disease processes also interact mechanis-
tically at a cellular level, probably in a manner that exacer-
bates both. However, partly because it has proven difficult 
to model either of these diseases accurately individually, let 
alone in combination, it has been difficult to determine the 
extent of that interaction or to establish which of the many 
potential mechanisms are biologically relevant.
This review covers some of the evidence of pathophysi-
ological interaction between CVD and AD and considers 
possible mechanisms and therapeutic implications.
Clinical and pathological associations 
between CVD and AD
CVD and AD share many risk factors, including APOE ε4 
[102, 141]; diabetes mellitus [139]; atrial fibrillation [38, 
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thy and degenerative changes affecting capillaries, and many 
have ischaemic parenchymal abnormalities. Structural vas-
cular disease contributes to the ischaemic abnormalities in 
some patients with AD. However, the stereotyped progression 
of hypoperfusion in this disease, affecting first the precuneus 
and cingulate gyrus, then the frontal and temporal cortex and 
lastly the occipital cortex, suggests that other factors are more 
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oxygen and glucose falls in late disease, functional MRI, near 
infrared spectroscopy to measure the saturation of haemoglo-
bin by oxygen, and biochemical analysis of myelin proteins 
with differential susceptibility to reduced oxygenation have 
all shown that the reduction in blood flow in AD is primarily 
a problem of inadequate blood supply, not reduced metabolic 
demand. Increasing evidence points to non-structural vascu-
lar dysfunction rather than structural abnormalities of vessel 
walls as the main cause of cerebral hypoperfusion in AD. Sev-
eral mediators are probably responsible. One that is emerg-
ing as a major contributor is the vasoconstrictor endothelin-1 
(EDN1). Whilst there is clearly an additive component to the 
clinical and pathological effects of hypoperfusion and AD, 
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ease processes also interact mechanistically at a cellular level 
in a manner that exacerbates both. The elucidation of some of 
the mechanisms responsible for hypoperfusion in AD and for 
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123]; ‘non-Mediterranean’ diet [87]; hyperhomocysteinae-
mia [92]; midlife hypertension, obesity and hypercholes-
terolaemia [30, 104, 160]; and, of course, age. The pres-
ence of vascular risk factors was reported to predict the 
development of AD or the conversion from mild cognitive 
impairment (MCI) to AD [35, 61, 90, 99]. Not all studies 
have found an association between vascular risk factors and 
AD [31, 134], and there are several potential confounders 
that should be considered in interpreting studies of shared 
risk factors or overlapping pathology, particularly as CVD 
and AD also overlap clinically. Concurrent ischaemic cer-
ebrovascular disease may simply lower the threshold for 
clinical manifestation of AD pathology [64, 134, 143, 
149]. Conversely, a history of hypertension or diabetes in 
patients with AD may bias clinicians towards a misdiagno-
sis of vascular dementia, underestimating the contribution 
of AD. The timing of several of the putative shared risk 
factors is of interest—coincident with the initial, presymp-
tomatic deposition of Aβ in midlife (and in some studies 
associated with the extent of that presymptomatic deposi-
tion), rather than the maximum severity of disease as would 
be expected if the effects of these risk factors on CVD and 
AD were simply additive. Meta-analysis of data from three 
large-scale genome-wide association studies highlighted 
the involvement of cardiovascular disease-related pathways 
in AD [94].
Abnormalities broadly described as ‘cerebrovascular’ 
are common in AD. The relevant neuropathological litera-
ture was reviewed in detail by Attems and Jellinger [8]. 
In most cases of neuropathologically confirmed AD, post-
mortem examination also reveals parenchymal vascular 
disease—both Aβ amyloid angiopathy and arterioloscle-
rotic small vessel disease (SVD) [75]. Cerebral infarcts or 
foci of haemorrhage can be demonstrated in over 50 % of 
AD brains, a figure that rises with age [46, 74, 75, 152]. 
Yet, other studies did not find any relationship between the 
burden of ischaemic vascular pathology and AD [31, 143].
Some studies suggest that AD is also associated with 
extracerebral atherosclerotic disease [65]. AD was associ-
ated with coronary artery disease in one study [151] but two 
other studies found no relationship between the severity of 
coronary artery disease and the Aβ plaque load [37, 86].
In several large post-mortem cohorts, AD was associ-
ated with atherosclerosis of the Circle of Willis [13, 67, 
135, 172]. The age- and sex-adjusted severity of the ath-
erosclerosis correlated with neuritic plaque [13, 67, 135, 
172], tangle [13, 135, 172] and CAA severity scores [172], 
independent of APOE genotype [13, 172]. In contrast, there 
was no relationship between severity of the atherosclerosis 
and AD pathology in a series of elderly Japanese [73] or 
in the Baltimore Longitudinal Study of Aging cohort [37]. 
The explanation for the discrepant finding between these 
studies is not clear.
Two recent biomarker studies provided additional evi-
dence of an association between CVD and AD. Hughes 
et al. [69] looked at the relationship between pulse wave 
velocity (an indicator of artery wall stiffness) and cerebral 
accumulation of Aβ over 2 years, as measured by positron 
emission tomography with Pittsburgh compound B, in 82 
non-demented people aged 83 years or older. The authors 
found a significant relationship between vascular stiffness 
in larger central arteries (as indicated by carotid-femoral 
and heart-femoral pulse wave velocity) and cerebral Aβ 
accumulation over the two-year period. In another study, 
Kester et al. [83] analysed brain magnetic resonance imag-
ing (MRI) findings and cerebrospinal fluid (CSF) tau and 
Aβ levels in 914 consecutive participants in the Amsterdam 
Dementia Cohort. The cohort included 30 people with a 
clinical diagnosis of vascular dementia, and 337 who had 
subjective memory complaints but were normal on cogni-
tive testing. In both groups, white matter hyperintensities 
were associated with reduced Aβ42 in the CSF, as in AD. 
Microbleeds were associated with lower CSF Aβ42 in the 
vascular dementia group and higher CSF tau in the partici-
pants with subjective memory complaints. The associations 
were largely attributable to the APOE ϵ4 carriers in these 
groups.
Structural disease of cerebral blood vessels 
in ageing in AD
Most patients with AD have Aβ amyloid angiopathy. Arte-
riolar Aβ amyloid angiopathy is demonstrable post-mortem 
in over 90 % of patients with AD compared with about 
30 % of elderly controls [27, 44, 50, 95, 98, 101, 161, 162, 
171]. The angiopathy predominantly affects the cerebral 
leptomeninges and cortex but sometimes also the cerebel-
lum and, very occasionally, the brain stem. It tends to be 
more severe in AD than controls, particularly in APOE 
ϵ4-positive patients [27, 52, 131, 142]. In controls, arte-
riolar Aβ amyloid angiopathy is more strongly associated 
with APOE ϵ2 [95].
Accumulation of Aβ amyloid in cerebral arterioles may 
be accompanied by its accumulation in capillaries, a find-
ing strongly associated with APOE ϵ4 and usually also 
with AD [1, 7, 95, 157]. In a series of 51 AD cases and 14 
controls assessed independently by neuropathologists in 
three different centres, capillary amyloid angiopathy was 
detected in 35–45 % of the AD cases, predominantly in the 
occipital lobe, but in only a single control brain [95].
It is unclear whether or not patients with AD are more 
likely to have (non-amyloid) SVD. Numerous imaging and 
pathological studies have reported an increased prevalence 
of ‘small vessel disease’ in AD but most have conflated 
parenchymal ischaemic lesions—particularly in the white 
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matter—with structural disease of cerebral blood vessels. 
APOE genotype influences the likelihood of ischaemic 
changes in AD. Morgen et al. [109] found that AD carriers 
of the APOE ϵ4 allele had a significantly greater volume of 
white matter hyperintensities than did non-carriers.
Whilst it is possible that many of the ischaemic lesions 
in patients with AD are attributable to cerebral SVD, some 
may have resulted from amyloid angiopathy or basal artery 
atherosclerosis, and a range of extracranial processes may 
also have contributed, including atherothrombotic or cho-
lesterol emboli from carotid or aortic plaques, orthostatic 
hypotension [9, 81, 82, 150], cardiac valvular disease 
and cardiac arrhythmias [153], particularly atrial fibrilla-
tion [38, 123]. To try to address this, some of the studies 
excluded or adjusted for cardiovascular risk factors [140] 
but there remains a paucity of direct evidence linking SVD 
and AD, or indeed linking SVD and white matter lesions 
in AD: a post-mortem study of 125 cases of AD did not 
find any association between several objective measures of 
white matter damage (extent of immunolabelling for glial 
fibrillary acidic protein, axonal accumulation of Aβ precur-
sor protein, axon density in superficial and deep white mat-
ter, intensity of staining for myelin) and severity of basal 
artery atherosclerosis, cerebral arteriolosclerosis or Aβ 
amyloid angiopathy, or APOE genotype [26].
Indirect evidence that SVD is more marked in AD comes 
from functional MRI analysis of regional cerebrovascular 
resistance (CVRi). In a study of CVRi in 12 patients with 
AD, 23 with MCI and 46 normal elderly controls, Nation 
et al. [114] found that cerebrovascular resistance was 
increased in several regions in AD and, to a lesser extent, 
in MCI. The increase was most marked in the thalamus 
and caudate nucleus, regions that are spared in Aβ amyloid 
angiopathy but have a predilection for SVD. Limitations 
of the study included the small cohort size and the use of 
non-contemporaneous measurements of peripheral rather 
than central blood pressure to calculate the CVRi, and in 
the absence of neuropathological confirmation the precise 
substrate of the increase in vascular resistance remains a 
matter of speculation.
Several studies have reported that the degeneration of 
cerebral capillaries in AD exceeds that in age-matched 
controls [10, 25, 70, 144]. The degeneration affects both 
endothelial cells and pericytes and leads eventually to an 
increase in the number of ‘string’ vessels consisting solely 
of tubes of collagen. This is not accompanied by a compen-
satory increase in the formation of new capillaries [11, 70, 
158]. The degeneration of pericytes and endothelial cells is 
probably interrelated.
CVD exacerbates neurological dysfunction 
and brain damage in AD
The most obvious impact of CVD is on cerebral perfu-
sion. There is a substantial literature documenting the asso-
ciation of Aβ amyloid angiopathy and SVD with infarcts 
(Fig. 1) and other ischaemic abnormalities [21, 23, 32, 33, 
43, 45, 121, 122, 133, 134, 136, 161]. The mechanisms 
include susceptibility to thrombosis [21, 97], permanent 
reduction in blood flow as a result of reduced calibre of 
more severely affected blood vessels, and impaired modu-
lation of the calibre in response to haemodynamic stress 
and alteration in metabolic demand.
Patients with AD have impaired autoregulation (i.e. 
reduced ability to maintain cerebral perfusion when 
Fig. 1  Infarction associated 
with Aβ amyloid angiopathy. 
a Microinfarct in cerebral 
cortex. The lesion is rarefied 
and gliotic, and includes a few 
macrophages. b Aβ immuno-
histochemistry on an adjacent 
section revealed moderately 
severe Aβ amyloid angiopathy. 
Note the circumferential deposi-
tion of Aβ in a sulcal arteriole 
overlying the microinfarct. Bar 
250 μm
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perfusion pressure changes, usually as a result of hypo-
tension) and reduced vasomotor reactivity to hypercap-
nia [36]. Patients with probable Aβ amyloid angiopathy 
(diagnosed according to the Boston criteria [84]) also 
show neurovascular decoupling, as evidenced by impaired 
functional hyperaemia [39, 130] (i.e. a reduced regional 
increase in blood flow in response to increased local meta-
bolic demand). Similar abnormalities in regulation of cer-
ebral blood flow were demonstrated in mouse models of 
cerebral Aβ accumulation [71, 117] and Aβ amyloid angi-
opathy [129, 147]. In patients with Aβ amyloid angiopa-
thy, reduced primary visual cortex fMRI responsiveness to 
a visual task correlated with the volume of white matter 
hyperintensities, an indicator of the severity of white matter 
ischaemia [130].
In a series of studies of human brain tissue and animal 
models, Weller, Carare, Hawkes and colleagues showed 
that interstitial fluid drains from the brain along perivascu-
lar spaces and basement membranes [164, 174], and that 
Aβ within the interstitial fluid tends to precipitate within 
the perivascular basement membranes [165, 166]. Further 
evidence that Aβ amyloid angiopathy reflected the precipi-
tation of Aβ from the interstitial fluid came from the find-
ing of Jucker and colleagues that neuron-specific overex-
pression of Aβ precursor protein caused the development of 
Aβ amyloid angiopathy in APP23 mice [22, 63]. Vascular 
deposition of Aβ is increased by possession of APOE ϵ4 
[27]; this is probably partly related to elevation of the ratio 
Aβ40:42 [48, 63] and partly to alterations in the composi-
tion of the perivascular basement membranes [60]. Vascular 
deposition of Aβ is also increased if drainage is impeded 
by Aβ amyloid angiopathy or by age-related changes to 
the perivascular basement membranes [58, 59, 76, 166]. 
The full range of downstream effects of impeded drainage 
of solutes in Aβ amyloid angiopathy remains to be deter-
mined. One probable consequence is an increase in the 
phosphorylation of tau, as evidenced by the more abundant 
neurofibrillary pathology around Aβ-laden than non-Aβ-
laden parenchymal arterioles in AD (Fig. 2) [169]. A simi-
lar increase in neurofibrillary pathology was demonstrated 
adjacent to parenchymal arterioles in the amyloid angiopa-
thy of familial British dementia, in which there is vascular 
deposition of ABri [66], which, like vascular Aβ, probably 
impedes the drainage of interstitial fluid.
Other ways in which AD-associated structural vascu-
lar disease exacerbates neurological dysfunction and brain 
damage include increased susceptibility to haemorrhage 
and, possibly, impaired blood–brain barrier (BBB) func-
tion. Carrano et al. [24] noted the loss of several compo-
nents of endothelial tight junctions in Aβ-laden capillaries 
in post-mortem brain tissue from patients with Aβ amy-
loid angiopathy, and similar findings were documented in 
several in vitro and ex vivo experimental studies, in which 
exposure of endothelial cells to Aβ40 or Aβ42 caused loss 
or mislocation of tight junction proteins [57, 85, 100, 154]. 
Hartz et al. [57] reported that 2 of 19 patients who fulfilled 
clinical criteria for probable Aβ amyloid angiopathy had 
MRI evidence of BBB leakage and posterior reversible 
encephalopathy syndrome.
Degeneration of pericytes probably contributes to the 
impairment of BBB function in AD. In mice pericytes 
were shown to be needed for maintenance of the blood–
brain barrier and capillary perfusion [3, 14]. Sengillo et al. 
[144] found the loss of pericytes in cerebral cortex and hip-
pocampus from AD patients to correlate with the extent of 
disruption of the blood–brain barrier, as demonstrated by 
extravasation of immunoglobulin G and perivascular dep-
osition of fibrin. In contrast, a study of a range of mouse 
Fig. 2  Perivascular tau associ-
ated with Aβ amyloid angiopa-
thy. a Arteriolar and dyshoric 
deposition of Aβ in a patient 
with severe amyloid angiopathy. 
b Immunolabelling of an adja-
cent section for phospho-tau 
showed accentuated accumula-
tion of tau around the affected 
arteriole. Bar 250 μm
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models of AD did not find increased permeability of the 
BB to antibodies [17].
Numerous studies have documented that patients with 
Aβ amyloid angiopathy are prone to cerebral haemorrhage, 
particularly lobar haemorrhage and cortical microhaemor-
rhage (Fig. 3) [43, 50, 51, 97, 111, 115, 131, 161, 171]. 
Both the ε2 and ε4 alleles of APOE increase the risk of Aβ 
amyloid angiopathy-associated lobar haemorrhage [52, 53, 
116]; ε4 may do so by promoting the accumulation of Aβ 
in the walls of arterioles, and ε2 by promoting the devel-
opment of vasculopathic changes, particularly fibrinoid 
necrosis, in the amyloid-laden vessels [54, 103]. Patients 
with Aβ amyloid angiopathy are also prone to develop 
superficial cortical siderosis [29, 93].
Cerebral hypoperfusion is an early feature of AD
Cerebral hypoperfusion is demonstrable several years 
before the onset of clinical AD. Imaging studies in peo-
ple with MCI [6, 18, 34], healthy carriers of the APOE ϵ4 
allele [89] and those with gene mutations known to cause 
autosomal dominant AD [15] have shown that the distri-
bution and spread of the hypoperfusion are highly stereo-
typed, and mirror the accumulation of Aβ amyloid within 
the brain parenchyma, particularly during the preclinical 
phases of disease. The first affected region is the precu-
neus, about 10 years before the development of dementia 
(Fig. 4). From there the hypoperfusion spreads to involve 
the cingulate gyrus and the lateral part of the parietal lobe, 
then the frontal and temporal lobes and eventually most of 
the cerebrum.
At least in preclinical early AD, the primary abnormality 
is one of inadequate blood supply, not reduced metabolic 
demand, in that the reduction in oxygenation is not com-
mensurate with the decline in blood flow. Several fMRI 
studies have found that the regional oxygen extraction frac-
tion (rOEF) is significantly elevated in AD, particularly in 
the parietal cortex [112, 113, 159], and Tarumi et al. [156] 
found the tissue oxygenation index (TOI, a measure of the 
saturation of haemoglobin by oxygen, determined by near 
infrared spectroscopy) to be significantly increased in the 
cortex in people with amnestic MCI. Were the decline in 
Fig. 3  Microhaemorrhage 
associated with Aβ amyloid 
angiopathy. a Accumulation of 
numerous haemosiderin-laden 
macrophages around a cortical 
arteriole with a strongly eosino-
philic wall. b The arteriole 
is immunopositive for Aβ, as 
demonstrated in this adjacent 
section. Bar 500 μm
Fig. 4  Stereotyped pattern of spread of hypoperfusion in AD. The 
arrows in this diagram indicate the progression of hypoperfusion, 
starting from the precuneus, well before the onset of dementia, and 
spreading to the rest of the parietal cortex and the cingulate gyrus, 
then the frontal and temporal cortex, largely sparing the occipital cor-
tex until late disease
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blood flow to be a response to decreased metabolic demand, 
the rOEF would be reduced and the TOI increased.
We recently developed a post-mortem biochemical 
method to study hypoperfusion in brain tissue [11, 12, 
96]. The method is based on the differential susceptibil-
ity of different myelin proteins to ischaemia. The myelin 
proteins are synthesised in the oligodendrocyte cell body 
and require energy-dependent transport to reach their sites 
of insertion into the myelin sheath. Myelin-associated gly-
coprotein (MAG) is one of the myelin proteins inserted 
furthest away from the cell body, in the adaxonal loop 
of myelin, the first part of the sheath to degenerate when 
blood supply is insufficient to meet the energy demands 
of the oligodendrocyte. Measurement of the ratio of MAG 
to another myelin protein such as proteolipid protein-1 
(PLP1), present throughout the myelin sheath, indicates the 
extent to which the blood supply meets the energy require-
ments of the oligodendrocyte (Fig. 5).
In the deep parietal white matter in an elderly cohort 
that included AD, VaD and cognitively normal cases, 
MAG:PLP1 showed a highly significant negative correla-
tion with severity of SVD and a highly significant positive 
correlations with the concentration of the vasoconstrictor 
endothelin-1 (EDN1) and with the concentration of vas-
cular endothelial growth factor (VEGF) [11, 12]. These 
biochemical relationships were confirmed in deep frontal 
white matter in an Oxford cohort that had excluded brains 
with more than mild AD or Lewy body pathology [12]. Our 
interpretation was that as SVD severity increased, EDN1 
production had been downregulated and VEGF production 
upregulated in response to the reduced tissue oxygenation.
Having established the utility of this post-mortem bio-
chemical assessment of ante-mortem oxygenation of brain 
tissue, we examined mid-frontal cortex from AD and con-
trol brains, to determine whether there was evidence that 
any reduction in perfusion exceeded the decline in meta-
bolic demand, and to try to identify possible mediators of 
hypoperfusion [158]. Our findings confirmed that perfusion 
was indeed pathologically reduced in AD. More recently, 
we examined precuneus, the region first affected by hypop-
erfusion in AD [106]. MAG:PLP1 in this region was 
reduced ~50 % in early AD (Braak stage III–IV). Although 
MAG:PLP1 in the precuneus remained low in advanced 
AD (stage V–VI), the reduction was less pronounced, pos-
sibly reflecting falling oxygen demand.
The main cause of cerebral hypoperfusion in AD 
is probably non‑structural vascular dysfunction 
rather than structural pathology
Although structural disease of blood vessels contributes to 
cerebral hypoperfusion in at least some patients with AD, 
we did not find Aβ amyloid angiopathy, SVD or reduced 
microvessel density to contribute significantly to the reduc-
tion in MAG:PLP1 in the frontal cortex, medial parietal 
cortex or parietal white matter in most cases [11, 106, 158]. 
It is of note that the consistent distribution of hypoperfu-
sion in early AD, involving the precuneus and, to a lesser 
extent, the cingulate gyrus, is not in a watershed region, 
as might be expected if postural hypotension or basal ath-
eroma were responsible. If SVD were the explanation, the 
hypoperfusion would be more likely to involve the deep 
white matter and basal ganglia. Lastly, the distribution of 
Aβ amyloid angiopathy is quite variable but it tends to be 
most severe in the occipital region, which is affected by 
hypoperfusion only in the late stages of AD.
There is a range of potential non-structural substrates of 
hypoperfusion in AD, several of which involve pathways that 
are strongly influenced by Aβ. Elevated Aβ was previously 
shown to cause vasoconstriction, reduce cerebral perfusion 
and prevent functional hyperaemia and autoregulation in 
mice transgenic for mutant human APP [71, 117, 118, 129]; 
to increase expression of endothelin-converting enzyme-1 
and -2 (ECE1 and ECE2) by human cerebrovascular endothe-
lial cells and neuroblastoma cells, respectively, leading to 
elevated EDN1 production [126–128]; to inhibit endothelial 
Fig. 5  Schematic illustration of the distribution of MAG (Pink dots) 
and PLP1 (Green dots) in the myelin sheath. When the supply of 
oxygen and glucose is insufficient to meet the metabolic needs of the 
oligodendrocyte, as occurs in hypoperfusion, the first part of the cell 
to degenerate is the adaxonal loop of myelin—the part of the oligo-
dendrocyte that is furthest away from the cell body (so-called dying-
back oligodendrogliopathy). Because MAG is restricted to the adax-
onal loop of myelin whereas PLP1 is widely distributed throughout 
the myelin sheath, hypoperfusion leads to greater loss of MAG than 
PLP1. In contrast, degeneration of nerve fibres causes loss of both 
MAG and PLP1. The severity of ante-mortem hypoperfusion can be 
assessed by measuring the MAG:PLP1 ratio
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nitric oxide synthase activity [49, 88], reducing endothelial 
production of the vasodilator nitric oxide; and to increase the 
neuronal expression and activity of angiotensin-converting 
enzyme (ACE) [107], which catalyses the production of the 
vasoconstrictor angiotensin II (AngII). Support for the path-
ogenic relevance of several of these experimental observa-
tions comes from the demonstration of elevated EDN1 level 
and ACE activity in post-mortem temporal and frontal cortex 
from patients with AD [105, 127, 158]. Aβ is a substrate of 
ECE1 and ECE2 [40–42, 124] and also of ACE [62, 68, 120], 
and it seems possible that the upregulation of production of 
EDN1 and AngII may be a side effect of over-activation of 
these enzyme systems by the accumulation of substrate.
More recently, we looked at MAG:PLP1, SVD, Aβ 
amyloid angiopathy, EDN1 level, ACE level and activity, 
and AngII level in precuneus from post-mortem human 
brains showing a spectrum of severity of AD (as indi-
cated by Braak tangle stage). We showed that MAG:PLP1 
declined in the precuneus even in early AD (i.e. in Braak 
stage III–IV disease) (Fig. 6). Indeed, despite progressive 
elevation in EDN1 concentration with disease progression, 
the MAG:PLP1 ratio was lower in early than in late AD 
(Fig. 7), presumably reflecting falling metabolic demand 
with increasing synaptic and neuronal damage. In the pre-
cuneus, unlike in the frontal cortex in advanced AD, we did 
not find elevation of ACE or AngII.
EDN1 in the cortex correlated highly significantly with 
the levels of both soluble and insoluble Aβ42, which we 
showed previously to upregulate neuronal ECE2 [126], but 
not with Aβ40, which we found to upregulate endothelial 
ECE1 [127]. The findings suggest that reduced oxygena-
tion of the precuneus in early AD is likely to result, at least 
in part, from Aβ42-mediated upregulation of ECE2.
MAG:PLP1 was also reduced in the parietal white mat-
ter in AD but here the decline correlated positively with the 
level of EDN1, in keeping with a protective vasodilatory 
response to reduced oxygenation. However, the decline 
of MAG:PLP1 in the white matter was associated with 
increasing EDN1 in the overlying cortex, perhaps reflecting 
EDN1-mediated vasoconstriction of perforating arterioles, 
which traverse the cortex to perfuse the white matter.
Although the main focus of studies of functional rather 
than structural vascular abnormalities has been on changes 
in arteriolar calibre, biochemical alterations in AD may also 
affect vascular permeability. In particular, several lines of 
evidence indicate that Aβ upregulates the plasma kallikrein-
kinin system, leading to the production of bradykinin, which 
causes dilatation and increased permeability of venules and, 
at higher concentration, dilatation of arterioles as well [2]. 
The activating enzyme, plasma kallikrein, circulates as an 
inactive zymogen and is activated through a cleavage pro-
cess involving Factor XIIa. Active plasma kallikrein cleaves 
its major substrate, high molecular weight kininogen (HK) 
to liberate bradykinin and activated HK. Aβ was shown to 
stimulate the production of bradykinin by endothelial cells 
[16, 146, 170]. Cerebroventricular infusion of Aβ40 in rats 
caused a 10-fold increase of bradykinin in the CSF and 
accumulation of degradation fragments of bradykinin in 
brain tissue [72]. Ashby et al. [5] demonstrated that plasma 
kallikrein mRNA was significantly increased in the frontal 
cortex in AD, and plasma kallikrein activity was signifi-
cantly increased in the frontal and temporal cortex in AD.
Cerebral hypoperfusion probably accelerates the 
progression of AD
As noted above, ischaemic brain damage is common in AD 
and in many cases contributes to the cognitive impairment. 
Fig. 6  Oxygenation of the precuneus is reduced in early Alzheimer’s 
disease. a Bar chart showing a reduction in the ratio of myelin gly-
coprotein (MAG) to proteolipid-1 protein (PLP-1) (MAG:PLP1) in 
the precuneus in AD. The bars indicate the mean and SEM. b Bar 
chart showing marked variation in MAG:PLP1 (P = 0.027) with dis-
ease stage. For this analysis, control and AD cases were combined 
and grouped according to Braak tangle stage (0–II, III–IV and V–VI). 
Post hoc analysis revealed that MAG:PLP1 was significantly reduced 
in early AD (Braak stage III–IV) compared to controls (P = 0.027). 
c Bar chart showing elevated vascular endothelial growth factor 
(VEGF), an independent marker of cerebral perfusion, in AD. d Scat-
terplot showing the highly significant negative correlation between 
MAG:PLP1 and VEGF concentration in the precuneus (r = −0.40, 
P = 0.0007). The best-fit linear regression line and 95 % confidence 
interval are superimposed. **P < 0.001, ***P < 0.0001. Reproduced 
with permission from [106]
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Ischaemia may also contribute to the progression of AD 
itself. Ischaemia in animal models, or its in vitro stimula-
tion, is associated with increased production of Aβ42 (for 
reviews see [31, 96]). Acute cerebral ischaemia or hypoxia 
caused overexpression of APP mRNA [145], upregulation 
of BACE1 mRNA and protein, increased β-secretase activ-
ity and the production of Aβ peptide  [55, 91, 167, 175]. 
BACE1 and Aβ (but not APP) level were also elevated in 
a chronic hypoperfusion model [176]. Transient ischaemia 
increased PSEN1 mRNA in the gerbil hippocampus [155] 
and repeated episodes of hypoxia enhanced β-secretase-
mediated cleavage of APP, and the level of APH-1a, another 
component of γ-secretase complex [91]. In other in vitro 
studies, hypoxia and/or oxidative modification reduced 
the activity of the Aβ-degrading enzymes neprilysin and 
insulin-degrading enzyme [47, 148, 163]. Lastly, transient 
cerebral ischaemia caused hyperphosphorylation of tau in 
cortical neurons [168].
Although most evidence that cerebral hypoperfusion 
may accelerate the progression of AD comes from in vitro 
and animal studies, some clinical observations support this 
possibility. In several clinical studies of cerebral blood flow 
and glucose utilisation in patients with a clinical diagnosis 
of AD or MCI, hypoperfusion predicted the development or 
rate of cognitive decline [19, 20, 28]. Patients who survived 
transient cerebral hypoperfusion as a result of cardiac arrest 
had elevated serum Aβ42 over several days [173]. And 
whilst that might be explained by non-specific ‘leakage’ 
of Aβ42 from damaged brain tissue, the same explanation 
could not be applied to the sustained elevation of serum 
Aβ42 in a study of patients with diffuse TBI with brain 
swelling and presumably at least some hypoperfusion, as 
they showed a concomitant reduction of Aβ42 in the CSF 
[108].
Implications for therapy
The identification of functionally important non-struc-
tural abnormalities of the cerebral vasculature in age-
ing and dementia, particularly in AD, raises the prospect 
that pharmacotherapy targeting the relevant biochemical 
pathways might slow the progression of dementia, by 
improving cerebral perfusion and reducing permeability 
of the BBB. An obvious potential target is the endothe-
lin system, for which there are already several well-tol-
erated antagonists. Bosentan, a non-selective endothelin 
receptor (EDNR) antagonist [138], has been licenced 
since 2001 for the treatment of pulmonary hypertension, 
another disease in which there is upregulation of ECEs 
and increased production of EDN1 [132, 137]. Bosentan 
produces significant, clinically useful, sustained improve-
ment in pulmonary blood flow and exercise tolerance 
in patients with pulmonary hypertension. Bosentan was 
also shown to prevent the attenuation of endothelium-
dependent aortic and carotid vasodilatation that is seen in 
Tg2576 mice (which overexpress a mutant form of APP 
bearing the Swedish double mutation). However, EDN1 
is thought to act on EDNRA receptors (the predominant 
EDN1 receptor type in cerebral vessels) to reduce CBF in 
AD, and there are selective EDNRA receptor antagonists 
such as zibotentan [56, 110] which offer potential advan-
tages over non-selective EDNR antagonists [125]. Other 
targets might include the plasma kallikrein-kinin [5] and 
renin-angiotensin systems [78]. The therapeutic poten-
tial of inhibiting the renin-angiotensin system in AD is 
attracting a great deal of interest and clinical investiga-
tion [4, 77, 79, 80, 119].
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Fig. 7  Reduced oxygenation of the precuneus in AD is associated 
with elevated endothelin-1 (EDN1). a Bar chart showing significantly 
increased EDN1 in AD within the precuneus. b Bar chart showing 
increased EDN1 levels in relation to disease severity when con-
trol and AD cases were subdivided according to Braak tangle stage 
(0–II, III–IV and V–VI) irrespective of the presence or absence of 
a history of dementia. Scatterplots showing the inverse correlation 
between EDN1 concentration and MAG:PLP1 ratio (r = −0.31) (c), 
and the positive correlation between EDN1 and VEGF (r = 0.29) (d). 
*P < 0.05, ***P < 0.001, ****P < 0.0001. Reproduced with permis-
sion from [106]
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